Poster Presentations featuring the latest advancements on anti-TROP2 ADCs (OBI 992 and OBI 902), AKR1C3 prodrug (OBI-3424), OBI’s novel ADC enabling technologies (GlycOBI® and ThiOBI®), and Globo H science TAIPEI, Taiwan, April 23, 2025 (GLOBE NEWSWIRE) — OBI Pharma, Inc. (TPEx: 4174. TWO) today announced nonclinical data for OBI-902, a potential best-in-class anti-TROP2 ADC developed […]
CryptoindustrypressesSenate Banking panel to reject efforts toexpand limits on stablecoinrewards
...
Read moreDetails